These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35936677)

  • 1. Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.
    Grave A; Blanc J; De Bari B; Pernot M; Boulbair F; Noirclerc M; Vienot A; Kim S; Borg C; Boustani J
    Front Oncol; 2022; 12():918271. PubMed ID: 35936677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
    Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
    BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
    Kim S; Meurisse A; Spehner L; Stouvenot M; François E; Buecher B; André T; Samalin E; Jary M; Nguyen T; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; de la Fouchardiere C; Boulbair F; Lakkis Z; Klajer E; Jacquin M; Taieb J; Vendrely V; Vernerey D; Borg C
    Ther Adv Med Oncol; 2020; 12():1758835920975356. PubMed ID: 33329760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
    Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C
    Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
    Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
    Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
    Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
    Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.
    Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
    Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
    BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Telomerase CD4
    Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial.
    Debernardi A; Meurisse A; Prétet JL; Guenat D; Monnien F; Spehner L; Vienot A; Roncarati P; André T; Abramowitz L; Molimard C; Mougin C; Herfs M; Kim S; Borg C
    Front Oncol; 2022; 12():941676. PubMed ID: 36313663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
    Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
    Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
    Eng C; Jácome AA; Das P; Chang GJ; Rodriguez-Bigas M; Skibber JM; Wolff RA; Qiao W; Xing Y; Sethi S; Ohinata A; Crane CH
    Clin Colorectal Cancer; 2019 Dec; 18(4):301-306. PubMed ID: 31350201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma.
    Gordeyev SS; Rasulov AO; Gorbounova VA; Tkachev SI; Glebovskaya VV; Fedyanin MY; Besova NS; Surayeva YE
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):623-629. PubMed ID: 28766008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
    Vendrely V; Ronchin P; Minsat M; Le Malicot K; Lemanski C; Mirabel X; Etienne PL; Lièvre A; Darut-Jouve A; de la Fouchardière C; Giraud N; Breysacher G; Argo-Leignel D; Thimonnier E; Magné N; Abdelghani MB; Lepage C; Aparicio T;
    Radiother Oncol; 2023 Sep; 186():109742. PubMed ID: 37315583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
    Kim S; Vendrely V; Saint A; André T; Vaflard P; Samalin E; Pernot S; Bouché O; Zubir M; Desrame J; de la Fouchardière C; Smith D; Ghiringhelli F; Vienot A; Jacquin M; Klajer E; Nguyen T; François É; Taieb J; Le Malicot K; Vernerey D; Meurisse A; Borg C
    Exp Hematol Oncol; 2023 Jul; 12(1):63. PubMed ID: 37480095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
    Voskuilen CS; van de Kamp MW; Schuring N; Mertens LS; Noordzij A; Pos F; van Rhijn BWG; van der Heijden MS; Schaake EE
    Radiother Oncol; 2020 Sep; 150():275-280. PubMed ID: 32768507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
    Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
    Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
    Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
    J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.